Operaciones 10x Genomics, Inc. - TXG CFD
Agregar a Favoritos- Resumen
- Datos históricos
- Eventos
- Cuenta de resultados
- Balance de situación
- Flujo de caja
- Propiedad
Diferencial | 0.14 | ||||||||
Tarifa nocturna posición alcista
Long position overnight fee
Ir a la plataforma | -0.024874% | ||||||||
Tarifa nocturna posición bajista
Short position overnight fee
Ir a la plataforma | 0.002651% | ||||||||
Horario tarifa nocturna | 21:00 (UTC) | ||||||||
Cantidad comercializada mínima | 1 | ||||||||
Divisa | USD | ||||||||
Margen | 20% | ||||||||
Mercado de valores | United States of America | ||||||||
Comisión por operación | 0% |
*Information provided by Capital.com
Cierre previo* | 51.97 |
Abrir* | 53.18 |
Cambio de 1 año* | -28.68% |
Rango del día* | 53.18 - 56.09 |
Rango de 52 semanas | 23.81-83.34 |
Volumen medio (10 días) | 754.85K |
Volumen medio (3 meses) | 21.21M |
Capitalización de mercado | 6.00B |
Ratio P/E | -100.00K |
Acciones en circulación | 115.36M |
Ingresos | 516.41M |
EPS | -1.46 |
Dividendo (Rendimiento %) | N/A |
Beta | 1.74 |
Próxima fecha de resultados | May 2, 2023 |
"Todos los datos son proporcionados por Refinitiv, excepto los datos marcados con un asterisco, que son *datos proporcionados por Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Cierre | Change | Change (%) | Apertura | High | Low |
---|---|---|---|---|---|---|
Mar 31, 2023 | 55.73 | 3.30 | 6.29% | 52.43 | 56.16 | 52.01 |
Mar 30, 2023 | 51.97 | 0.76 | 1.48% | 51.21 | 52.32 | 51.07 |
Mar 29, 2023 | 50.69 | 1.41 | 2.86% | 49.28 | 50.98 | 49.00 |
Mar 28, 2023 | 48.81 | -0.45 | -0.91% | 49.26 | 49.42 | 48.27 |
Mar 27, 2023 | 49.70 | -0.68 | -1.35% | 50.38 | 51.52 | 49.29 |
Mar 24, 2023 | 50.12 | 2.16 | 4.50% | 47.96 | 50.30 | 47.65 |
Mar 23, 2023 | 48.97 | 0.03 | 0.06% | 48.94 | 51.49 | 48.48 |
Mar 22, 2023 | 48.69 | -1.39 | -2.78% | 50.08 | 51.08 | 48.61 |
Mar 21, 2023 | 50.03 | 1.83 | 3.80% | 48.20 | 50.25 | 47.91 |
Mar 20, 2023 | 47.76 | 0.30 | 0.63% | 47.46 | 48.56 | 46.76 |
Mar 17, 2023 | 48.08 | -1.09 | -2.22% | 49.17 | 49.71 | 47.66 |
Mar 16, 2023 | 50.25 | 2.49 | 5.21% | 47.76 | 50.90 | 47.60 |
Mar 15, 2023 | 48.54 | 1.45 | 3.08% | 47.09 | 49.32 | 47.08 |
Mar 14, 2023 | 48.63 | 0.07 | 0.14% | 48.56 | 49.52 | 48.06 |
Mar 13, 2023 | 47.44 | 3.47 | 7.89% | 43.97 | 49.32 | 43.97 |
Mar 10, 2023 | 44.93 | -1.55 | -3.33% | 46.48 | 46.49 | 43.15 |
Mar 9, 2023 | 47.00 | -1.65 | -3.39% | 48.65 | 49.98 | 46.93 |
Mar 8, 2023 | 48.95 | 1.16 | 2.43% | 47.79 | 49.49 | 47.24 |
Mar 7, 2023 | 48.16 | 0.10 | 0.21% | 48.06 | 49.75 | 47.48 |
Mar 6, 2023 | 48.39 | -2.30 | -4.54% | 50.69 | 50.80 | 48.13 |
10x Genomics, Inc. Events
Hora (UTC) (UTC) | País | Evento |
---|---|---|
No events scheduled |
- Anual
- Trimestral
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Ingresos totales | 516.409 | 490.49 | 298.845 | 245.893 | 146.313 |
Ingresos | 516.409 | 490.49 | 298.845 | 245.893 | 146.313 |
Coste de los ingresos, total | 120.386 | 74.091 | 58.468 | 61.033 | 28.661 |
Beneficio bruto | 396.023 | 416.399 | 240.377 | 184.86 | 117.652 |
Gastos totales de explotación | 684.353 | 542.743 | 834.508 | 276.466 | 257.077 |
Gastos de venta/general/administración Gastos, total | 298.3 | 257.56 | 199.726 | 130.834 | 87.936 |
Investigación y desarrollo | 265.667 | 211.752 | 570.923 | 83.097 | 109.9 |
Other Operating Expenses, Total | 0 | -0.66 | 1.27 | 1.502 | 30.58 |
Ingresos de explotación | -167.944 | -52.253 | -535.663 | -30.573 | -110.764 |
Ingresos por intereses (gastos), netos No operativos | 6.171 | -0.66 | -0.15 | -0.274 | -1.385 |
Otros, netos | -0.198 | -0.802 | 1.337 | -0.186 | -0.249 |
Ingresos netos antes de impuestos | -161.971 | -53.715 | -534.476 | -31.033 | -112.398 |
Ingresos netos después de impuestos | -166 | -58.223 | -542.731 | -31.251 | -112.485 |
Beneficio neto antes de partidas extra. Elementos | -166 | -58.223 | -542.731 | -31.251 | -112.485 |
Total de partidas extraordinarias | |||||
Ingresos netos | -166 | -58.223 | -542.731 | -31.251 | -112.485 |
Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -166 | -58.223 | -542.731 | -31.251 | -112.485 |
Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -166 | -58.223 | -542.731 | -31.251 | -112.485 |
Beneficio neto diluido | -166 | -58.223 | -542.731 | -31.251 | -112.485 |
Promedio ponderado de acciones diluidas | 113.859 | 110.348 | 101.152 | 96.2416 | 93.8497 |
BPA diluido sin partidas extraordinarias | -1.45795 | -0.52763 | -5.36552 | -0.32471 | -1.19857 |
BPA normalizado diluido | -1.45795 | -0.52763 | -5.33904 | -0.32471 | -1.19857 |
Gastos (ingresos) extraordinarios | 0 | 0 | 4.121 |
Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
---|---|---|---|---|---|
Ingresos totales | 156.232 | 131.072 | 114.609 | 114.496 | 143.53 |
Ingresos | 156.232 | 131.072 | 114.609 | 114.496 | 143.53 |
Coste de los ingresos, total | 36.827 | 30.377 | 27.704 | 25.478 | 27.598 |
Beneficio bruto | 119.405 | 100.695 | 86.905 | 89.018 | 115.932 |
Gastos totales de explotación | 179.328 | 171.068 | 177.726 | 156.231 | 159.36 |
Gastos de venta/general/administración Gastos, total | 78.887 | 73.401 | 79.337 | 66.675 | 69.877 |
Investigación y desarrollo | 63.614 | 67.29 | 70.685 | 64.078 | 61.885 |
Gastos (ingresos) extraordinarios | 0 | 0 | |||
Other Operating Expenses, Total | 0 | 0 | 0 | 0 | |
Ingresos de explotación | -23.096 | -39.996 | -63.117 | -41.735 | -15.83 |
Ingresos por intereses (gastos), netos No operativos | 2.69 | 1.911 | 1.129 | 0.441 | -0.168 |
Otros, netos | 3.995 | -1.95 | -1.843 | -0.4 | 0.005 |
Ingresos netos antes de impuestos | -16.411 | -40.035 | -63.831 | -41.694 | -15.993 |
Ingresos netos después de impuestos | -17.215 | -41.914 | -64.458 | -42.413 | -18.449 |
Beneficio neto antes de partidas extra. Elementos | -17.215 | -41.914 | -64.458 | -42.413 | -18.449 |
Ingresos netos | -17.215 | -41.914 | -64.458 | -42.413 | -18.449 |
Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -17.215 | -41.914 | -64.458 | -42.413 | -18.449 |
Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -17.215 | -41.914 | -64.458 | -42.413 | -18.449 |
Beneficio neto diluido | -17.215 | -41.914 | -64.458 | -42.413 | -18.449 |
Promedio ponderado de acciones diluidas | 114.767 | 114.112 | 113.575 | 112.966 | 111.913 |
BPA diluido sin partidas extraordinarias | -0.15 | -0.3673 | -0.56754 | -0.37545 | -0.16485 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | ||
BPA normalizado diluido | -0.15 | -0.3673 | -0.56754 | -0.37545 | -0.16485 |
- Anual
- Trimestral
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Total Activo Corriente | 747.591 | 774.366 | 480.84 | 106.236 | 68.107 |
Efectivo e inversiones a corto plazo | 587.447 | 663.603 | 424.166 | 65.08 | 47.857 |
Efectivo y Equivalentes | 587.447 | 663.603 | 424.166 | 65.08 | 47.857 |
Total deudores, neto | 85.254 | 51.208 | 33.371 | 29.566 | 13.341 |
Accounts Receivable - Trade, Net | 85.254 | 51.208 | 33.371 | 28.088 | 13.341 |
Total Inventory | 59.966 | 29.959 | 15.27 | 8.57 | 4.838 |
Prepaid Expenses | 13.896 | 13.029 | 8.033 | 3.02 | 2.071 |
Total Assets | 1018.83 | 929.341 | 605.923 | 124.31 | 75.609 |
Property/Plant/Equipment, Total - Net | 230.41 | 119.823 | 48.821 | 11.127 | 6.925 |
Property/Plant/Equipment, Total - Gross | 279.431 | 150.325 | 67.876 | 25.21 | 17.958 |
Accumulated Depreciation, Total | -49.021 | -30.502 | -19.055 | -14.083 | -11.033 |
Other Long Term Assets, Total | 10.917 | 12.798 | 76.262 | 6.947 | 0.577 |
Total Current Liabilities | 110.357 | 118.126 | 63.049 | 32.362 | 22.141 |
Accounts Payable | 17.351 | 4.709 | 13.028 | 8.792 | 5.443 |
Accrued Expenses | 75.821 | 92.326 | 30.035 | 12.118 | 8.959 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0 | 9.882 | 4.187 | 4.224 | |
Other Current Liabilities, Total | 17.185 | 21.091 | 10.104 | 7.265 | 3.515 |
Total Liabilities | 201.258 | 190.269 | 185.84 | 101.053 | 29.704 |
Total Long Term Debt | 0 | 0 | 19.837 | 25.489 | 6.335 |
Long Term Debt | 0 | 19.837 | 25.489 | 6.335 | |
Other Liabilities, Total | 90.901 | 72.143 | 102.954 | 43.202 | 1.228 |
Total Equity | 817.568 | 739.072 | 420.083 | 23.257 | 45.905 |
Redeemable Preferred Stock | 0 | 243.244 | 158.414 | ||
Common Stock | 0.002 | 0.002 | 0.002 | 0.001 | 0.001 |
Additional Paid-In Capital | 1680.86 | 1544.22 | 682.494 | 11.165 | 6.136 |
Retained Earnings (Accumulated Deficit) | -863.321 | -805.098 | -262.367 | -231.116 | -118.631 |
Other Equity, Total | 0.022 | -0.05 | -0.046 | -0.037 | -0.015 |
Total Liabilities & Shareholders’ Equity | 1018.83 | 929.341 | 605.923 | 124.31 | 75.609 |
Total Common Shares Outstanding | 112.515 | 108.486 | 96.2416 | 93.8497 | 93.8497 |
Other Current Assets, Total | 1.028 | 16.567 | |||
Intangibles, Net | 25.397 | 22.354 | |||
Goodwill, Net | 4.511 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Total Activo Corriente | 697.335 | 747.591 | 744.104 | 757.174 | 745.716 |
Efectivo e inversiones a corto plazo | 539.323 | 587.447 | 600.44 | 621.958 | 617.195 |
Efectivo y Equivalentes | 312.487 | 587.447 | 600.44 | 621.958 | 617.195 |
Total deudores, neto | 76.526 | 85.254 | 78.43 | 59.68 | 57.408 |
Accounts Receivable - Trade, Net | 76.526 | 85.254 | 78.43 | 59.68 | 57.408 |
Total Inventory | 63.697 | 59.966 | 51.141 | 44.087 | 38.507 |
Prepaid Expenses | 17.762 | 13.896 | 14.065 | 13.298 | 14.442 |
Other Current Assets, Total | 0.027 | 1.028 | 0.028 | 18.151 | 18.164 |
Total Assets | 1003.25 | 1018.83 | 990.572 | 977.579 | 954.033 |
Property/Plant/Equipment, Total - Net | 265.88 | 230.41 | 203.304 | 176.454 | 163.666 |
Property/Plant/Equipment, Total - Gross | 279.431 | 247.698 | 215.665 | 198.415 | |
Accumulated Depreciation, Total | -49.021 | -44.394 | -39.211 | -34.749 | |
Goodwill, Net | 4.511 | 4.511 | 4.511 | 4.511 | 4.511 |
Intangibles, Net | 24.764 | 25.397 | 26.041 | 26.693 | 27.342 |
Other Long Term Assets, Total | 10.761 | 10.917 | 12.612 | 12.747 | 12.798 |
Total Current Liabilities | 94.446 | 110.357 | 100.375 | 113.126 | 120.549 |
Accounts Payable | 18.956 | 17.351 | 17.037 | 16.181 | 15.578 |
Accrued Expenses | 59.913 | 75.821 | 69.92 | 85.598 | 95.307 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 15.577 | 17.185 | 13.418 | 11.347 | 9.664 |
Total Liabilities | 196.566 | 201.258 | 190.351 | 192.993 | 201.573 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Long Term Debt | 0 | ||||
Other Liabilities, Total | 102.12 | 90.901 | 89.976 | 79.867 | 81.024 |
Total Equity | 806.685 | 817.568 | 800.221 | 784.586 | 752.46 |
Common Stock | 0.002 | 0.002 | 0.002 | 0.002 | 0.002 |
Additional Paid-In Capital | 1714.86 | 1680.86 | 1644.9 | 1612.23 | 1569.06 |
Retained Earnings (Accumulated Deficit) | -905.734 | -863.321 | -844.872 | -827.701 | -816.649 |
Other Equity, Total | -2.443 | 0.022 | 0.194 | 0.058 | 0.048 |
Total Liabilities & Shareholders’ Equity | 1003.25 | 1018.83 | 990.572 | 977.579 | 954.033 |
Total Common Shares Outstanding | 113.276 | 112.515 | 111.537 | 110.74 | 109.589 |
Inversiones a corto plazo | 226.836 |
- Anual
- Trimestral
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Ingresos netos/Línea de salida | -166 | -58.223 | -542.731 | -31.251 | -112.485 |
Efectivo de actividades de explotación | -33.606 | -21.373 | -217.898 | 34.627 | -76.409 |
Efectivo de actividades de explotación | 25.368 | 21.118 | 14.012 | 7.066 | 3.905 |
Partidas no monetarias | 146.443 | 103.177 | 361.202 | 14.048 | 4.156 |
Cash Taxes Paid | 3.925 | 8.66 | 0.28 | -0.022 | -0.006 |
Intereses pagados en efectivo | 0.841 | 1.222 | 1.67 | 2.25 | 1.824 |
Cambios en el capital circulante | -39.417 | -87.445 | -50.381 | 44.764 | 28.015 |
Efectivo de actividades de inversión | -350.887 | -106.729 | -38.394 | -42.767 | -6.709 |
Gastos de capital | -131.661 | -101.278 | -38.394 | -42.767 | -6.709 |
Efectivo procedente de actividades de financiación | 15.817 | 35.297 | 468.906 | 414.59 | 105.367 |
Elementos de flujo de caja de financiación | -5.409 | -5.028 | -5.848 | 0 | |
Emisión (retiro) de acciones, neto | 21.226 | 40.325 | 506.01 | 414.59 | 86.628 |
Emisión (amortización) de deuda, neta | 0 | 0 | -31.256 | 0 | 18.739 |
Efectos del cambio de divisas | -0.044 | 0.234 | -0.463 | -0.045 | -0.018 |
Variación neta de la tesorería | -368.72 | -92.571 | 212.151 | 406.405 | 22.231 |
Otras partidas de flujo de caja de inversión, total | -219.226 | -5.451 |
Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -166 | -148.785 | -106.871 | -42.413 | -58.223 |
Cash From Operating Activities | -33.606 | -47.329 | -37.765 | -20.802 | -21.373 |
Cash From Operating Activities | 25.368 | 18.847 | 12.691 | 6.191 | 21.118 |
Non-Cash Items | 146.443 | 102.681 | 66.548 | 28.014 | 103.177 |
Cash Taxes Paid | 3.925 | 3.649 | 3.319 | 2.9 | 8.66 |
Cash Interest Paid | 0.841 | 0.841 | 0.841 | 0.841 | 1.222 |
Changes in Working Capital | -39.417 | -20.072 | -10.133 | -12.594 | -87.445 |
Cash From Investing Activities | -350.887 | -317.715 | -285.085 | -257.558 | -106.729 |
Capital Expenditures | -131.661 | -91.927 | -55.355 | -28.136 | -101.278 |
Other Investing Cash Flow Items, Total | -219.226 | -225.788 | -229.73 | -229.422 | -5.451 |
Cash From Financing Activities | 15.817 | 10.816 | 8.777 | 2.417 | 35.297 |
Financing Cash Flow Items | -5.409 | -5.409 | -5.409 | -5.409 | -5.028 |
Issuance (Retirement) of Stock, Net | 21.226 | 16.225 | 14.186 | 7.826 | 40.325 |
Issuance (Retirement) of Debt, Net | 0 | 0 | |||
Foreign Exchange Effects | -0.044 | -0.295 | -0.21 | -0.018 | 0.234 |
Net Change in Cash | -368.72 | -354.523 | -314.283 | -275.961 | -92.571 |
Nombre del Inversor | Tipo de inversor | Porcentaje pendiente | Acciones en propiedad | Cambio de acciones | Fechas de holding | Índice de rotación |
---|---|---|---|---|---|---|
Morgan Stanley Investment Management Inc. (US) | Investment Advisor/Hedge Fund | 9.4813 | 9210082 | -415196 | 2022-12-31 | LOW |
Baillie Gifford & Co. | Investment Advisor | 8.8556 | 8602235 | 158847 | 2022-12-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 8.6523 | 8404774 | 145652 | 2022-12-31 | LOW |
Paladin Capital Management, LLC | Investment Advisor | 8.3511 | 8112208 | 0 | 2022-03-31 | |
ARK Investment Management LLC | Investment Advisor | 4.4437 | 4316567 | -260247 | 2022-12-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 4.3422 | 4217954 | 207975 | 2022-12-31 | LOW |
Sands Capital Management, LLC | Investment Advisor | 3.3012 | 3206783 | -184394 | 2022-12-31 | LOW |
Fidelity Management & Research Company LLC | Investment Advisor | 3.2549 | 3161803 | -518131 | 2022-12-31 | LOW |
SRS Investment Management, LLC | Hedge Fund | 3.0939 | 3005427 | 0 | 2022-12-31 | LOW |
Generation Investment Management LLP | Investment Advisor/Hedge Fund | 2.6231 | 2548100 | -57577 | 2022-12-31 | LOW |
Nikko Asset Management Co., Ltd. | Investment Advisor/Hedge Fund | 2.2421 | 2177988 | -29270 | 2022-12-31 | LOW |
Credit Suisse Asset Management | Investment Advisor/Hedge Fund | 2.1979 | 2135038 | -17833 | 2022-12-31 | LOW |
T. Rowe Price Associates, Inc. | Investment Advisor | 2.018 | 1960300 | -337642 | 2022-12-31 | LOW |
Citadel Advisors LLC | Hedge Fund | 1.507 | 1463901 | 1108820 | 2022-12-31 | HIGH |
Brown Capital Management, LLC | Investment Advisor | 1.4964 | 1453630 | -161463 | 2022-12-31 | LOW |
Foresite Capital Management, LLC | Private Equity | 1.3985 | 1358528 | -1145000 | 2022-12-31 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 1.3854 | 1345749 | -18168 | 2022-12-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.3601 | 1321234 | 63324 | 2022-12-31 | LOW |
Millennium Management LLC | Hedge Fund | 1.2491 | 1213394 | 999487 | 2022-12-31 | HIGH |
JP Morgan Asset Management | Investment Advisor | 1.2158 | 1180996 | 27291 | 2022-12-31 | LOW |
¿Por qué operar con Capital.com? Nuestros números hablan por nosotros
Capital.com Group500K+
Traders
92K+
Clientes activos mensualmente
$53M+
Volumen mensual de inversión
$30M+
Retiros por mes
Calculadora de trading
Calcula tus P&L hipotéticas en el supuesto de haber abierto una operación con CFD en una fecha determinada (selecciona una fecha) y haberla cerrado en otra fecha (selecciona una fecha).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
10x Genomics, Inc. Company profile
Sobre 10X Genomics Inc
10x Genomics, Inc. es una empresa de tecnología de ciencias de la vida. Las soluciones integradas de la empresa incluyen instrumentos, consumibles y software para analizar sistemas biológicos. Sus productos incluyen Chromium Single Cell Gene Expression, Single Cell Immune Profiling, Single Cell assay for transposase accessible chromatin (ATAC) + Gene Expression, Single Cell ATAC, Spatial Gene Expression, Spatial Multiomics, y Targeted Gene Expression. Sus instrumentos incluyen Chromium X Series, Chromium Connect y Chromium Controller. Su tecnología Next GEM, que incluye chips y reactivos compatibles, se ofrece para la cartera de productos unicelulares. Su cartera de consumibles incluye chips microfluídicos, portaobjetos, reactivos y otros consumibles para sus soluciones Visium y Chromium. Las aplicaciones de la empresa incluyen el cribado de repeticiones palindrómicas cortas agrupadas y regularmente espaciadas (CRISPR), la citometría multiómica y el mapeo de receptores inmunitarios.
Industry: | Laboratory Diagnostic & Testing Substances |
6230 Stoneridge Mall Road
PLEASANTON
CALIFORNIA 94588
US
Cuenta de resultados
- Annual
- Quarterly
A la gente también le interesa
¿Aún estás buscando un bróker de confianza?
Únete a más de 500.000 traders de todo el mundo que eligen operar con Capital.com